Known ingredients, proven independently, powerful together.

Made with Collagen, Mānuka Honey + Hydroxyapatite, APIS® is a bioengineered wound product for the management of chronic and acute wounds that covers and protects wounds, absorbs exudate, and creates a moist wound environment.

THE APIS® DIFFERENCE

  • Published in multiple peer-reviewed publications demonstrating 4-8 week wound closure across both chronic and acute wounds 1-4*

  • Supports wound closure across the early stages of bacteria and inflammation to the late stages of proliferation and remodeling 5-7*

  • Supplied in an all-in-one sheet, APIS® is ready to apply in minutes, can be trimmed or folded, and naturally conforms to the wound bed for easy application

  • Clear billing pathway and positioned for stability in the evolving reimbursement landscape. Established HCPCS code, A2010, APIS®

Powerful Performance

Lower Pain Reported (4*)

4-8 week wound closure (1-3*)

99.99% bacteria reduction in 24 hrs (5*)

Inflammation reduction (6,7*)

Growth factor release (6,7*)

OUR MX® TECHNOLOGY FUELS APIS®

An Advanced Synthesis of Proven Materials

We meticulously deconstructed natural elements to reimagine and rebuild a new biomaterial, MX®, with a unique chemical fingerprint that transcends the sum of its parts.

  • SweetBio®’s MX® technology embodies a paradigm shift in biomaterials by liberating three natural ingredients from their limitations.

    The deliberate selection of ingredients by biomedical engineers has led to the creation of revolutionary wound healing products tailored to address the specific demands of the healing process.

  • A natural, porcine-derived extracellular matrix protein beneficial for cell migration, adhesion and proliferation (8)

  • 100% UMF-certified New Zealand Mānuka honey known for antibacterial and anti-inflammatory effects. (9)

  • A naturally occurring mineral known to bind proteins and promote healing via angiogenesis (10)

Effortless for Patients and Clinicians

  • APIS® is provided in a comfortable sheet and easily applied during patient's visit, conforming naturally to the wound bed.

  • For easy maintenance, APIS® dissolves in 7-14 days as the wound progresses with no painful removal process.

  • APIS® is positioned for stability in the evolving reimbursement landscape.

    Established HCPCS code, A2010, APIS®

  • APIS® is available in:

    APIS-16x16-2 1.6 x 1.6cm

    APIS-25x25-2 2.5 x 2.5cm

    APIS-50x50-2 5.0 x 5.0cm

    *Coming soon in 6.0 x 8.0cm

  • Under the supervision of a healthcare professional, APIS® is indicated for use in the management of wounds, including:

    • Full and partial thickness wounds

    • Pressure ulcers (stages I-IV)

    • Venous stasis ulcers

    • Diabetic ulcers

    • Surface wounds

    • Traumatic wounds (healing by secondary intention)

    • Surgical wounds

    • Abrasions

    • Donor site wounds

  • "My patients are doing unbelievably well and healing after the first application, which in a chronic wound is just such a rarity to see."

    — Physician with experience using 50+ applications of APIS®

  • "Traditionally, my wounds have taken 14-18 weeks to close. After 5 weeks of APIS®, my wound closed. I can easily take a shower again."

    — APIS® Patient

APIS® is Easily Applied

  • Prep

    Hydrate APIS® with saline for 1-2 minutes

  • Place

    Apply and gently press to contact the wound bed

  • Protect

    Cover with your preferred secondary dressing or wrap

APIS® in Action

DIABETIC FOOT ULCER (HEEL)

  • 60-year-old male with a history of diabetes mellitus, hypertension, peripheral vascular disease, peripheral neuropathy, and obesity.

  • Diabetic foot ulcer on the heel of the right foot. For 12 months, the wound was treated with various wound care products without resolution of closure.

  • The patient had 5 visits over 5 weeks with a total of 4 APIS® applications.

  • Near complete closure at week 4 with complete closure at week 5. 

*Pictures taken and shared with patient consent.

Backed by Evidence

  • Clinical Publication: 37 Patient Mohs Dermatologic Surgery RCT

    Published in Dermatologic Surgery, this randomized controlled trial (RCT) conducted by the Dermatology Department at Vanderbilt University Medical Center compared SweetBio®’s technology and secondary intention healing (SIH) to support wound closure post-Mohs. Results demonstrated improved wound healing with SweetBio®’s technology showing significant reduction in pain scores and favorable skin thickness.

    Download

  • Clinical Publication: 12 Patient Lower Extremity Chronic Wound Case Series

    Published in The International Journal of Lower Extremity Wounds, this clinical evaluation involved 5 physicians across 4 states using SweetBio®’s technology to treat non-healing chronic ulcers. Patients achieved 100% closure within 8 weeks, with a mean closure time of 4.1 weeks.

    Download

  • Clinical Publication: 8 Patient Mohs Dermatologic Surgery Case Series

    Published in Dermatologic Surgery, this clinical evaluation conducted by the Dermatology Department at Vanderbilt University Medical Center used SweetBio®’s technology to support wound closure post Mohs (skin cancer removal) surgery. Results demonstrated complete re-epithelialization was achieved within an average of 6 weeks.

    Download

  • Clinical Publication: 43 Patient Chronic Wound Healing in an Urban Hospital Wound Clinic

    Published in Wounds, this retrospective IRB-approved clinical evaluation assessed chronic wound closure rates using standard of care (SOC) or treatment with SweetBio®’s technology in an urban hospital wound clinic. In both groups, most wounds did not close for several reasons, mainly patient compliance. For wounds that did close, the average time to closure was two times faster for SweetBio®’s technology compared to SOC (7.4 weeks and 14.8 weeks, respectively; p < .05).

    Download

  • In Vitro Publication: Bacteria Reduction

    Published in Biomedical & Translational Science, this data demonstrates SweetBio®’s technology ability to significantly reduce both Staphylococcus Aureus and Pseudomonas Aeruginosa by 99.99% compared to a non-treated surface after 24 hours, in vitro.

    Download

  • In Vitro Publication: Controlling Inflammation and Growth Factors

    Published in the International Journal of Biomaterials, this data demonstrates SweetBio®’s technology ability to significantly decrease (to negligible levels) the expression of MMP-9 from macrophages and trigger the release of pro-regenerative growth factors from fibroblasts such as FGFb and VEGF, in vitro.

    Download

  • In Vitro Publication: Direct Comparison of Collagen Dressing vs. Manuka Honey Dressing vs. SweetBio®’s Technology

    Published in the International Journal of Molecular Sciences, this data highlights the superior comprehensive approach that SweetBio®’s technology has over collagen dressings and Manuka honey dressings, specifically comparing MMP-9/TIMP-1 ratios and pro-regenerative growth factor secretion, in vitro.

    Download

Frequently Asked Questions

APIS® OVERVIEW

  • Whether surgically created or stalled, APIS® can be used on most wounds. APIS® is FDA-cleared for the management of a variety of wounds, including surgical sites (Mohs, biopsies, etc.) and ulcers (diabetic, venous stasis, pressure).

    Indications:

    Full and Partial-Thickness Wounds

    Pressure Ulcers (Stages I-IV)

    Venous Stasis Ulcers

    Diabetic Ulcers

    Surface Wounds

    Traumatic Wounds

    Surgical Wounds

    Abrasions

    Donor Sites

  • Powered by a patented combination of 3 natural ingredients, APIS® is a one-of-a-kind solution backed by science. Ingredients:

    • Collagen Derivative: A natural extracellular matrix protein, an essential part of organic tissue. (8)

    • 100% UMF™-Certified New Zealand Mānuka Honey: Known for antibacterial properties and aiding in wound healing. (9)

    • Hydroxyapatite: A naturally occurring mineral known to add structural reinforcement to biomaterials and promote wound healing via angiogenesis and re-epithelialization. (10)

  • APIS® was created by SweetBio, Inc. Learn more about SweetBio's mission and values here.

  • APIS® is made with SweetBio®’s technology, MX™, which addresses the wound's microenvironment by balancing key variables known to heavily impact both early stages (i.e., homeostasis and inflammatory phases) and late stages (i.e., proliferation and remodeling phases) of the wound healing process. (5-7*)

  • There is no FDA-cleared claim for APIS® or any other Mānuka honey product on the market as an antibacterial product. However, Mānuka honey is well-researched for its antibacterial properties, and SweetBio®’s MX™ technology has demonstrated a 99.99% reduction in gram-positive and gram-negative bacteria in vitro, which is published in peer-reviewed journals. (5*)

  • APIS® uses medical‑grade, UMF‑certified Mānuka honey that is filtered and sterilized to remove environmental particles such as pollen. It does not contain components typically associated with bee‑ or pollen‑related allergic reactions. Individuals with severe allergies should still consult a clinician for personalized guidance.

  • HCPCS A2010, APIS

TIPS FOR THE BEST APIS® EXPERIENCE

  • SweetBio® will provide an easy-to-follow script for you to support your patient’s expectations.

    Email info@sweetbio.com for patient educational materials.

  • Since APIS® is made with natural ingredients, you might notice variations in shape, size, or color from one side to the other. That’s completely normal—and either side can be placed on the wound.

  • Use sterile saline to moisten APIS® for 1-2 minutes. This helps it soften, conform to the wound, and support a moist healing environment. As APIS® hydrates, it may curl or slightly bunch - after 1-2 minutes, APIS® will relax into a flat, soft sheet.

    APIS® should be wet, not soaking or dripping, to avoid saturating the secondary dressing. Note that APIS® may expand in length and width as it hydrates with saline.

  • You might notice a light scent when opening the pouch. It’s from the protein base of collagen and will fade within seconds.

  • APIS® must contact as much of the wound as possible and does not need to overlap the edges of the wound. Gently press to ensure it contacts the wound.

  • On average, APIS® dissolves in 7-14 days dependent on the wound environment. Apply a new APIS® product per your recommendation.

  • If APIS® hasn’t fully dissolved at the patient’s visit, do not remove it— simply add a saline if APIS® is dry and dress the wound with your preferred cover dressing.

  • Contraindications

    • Patients with sensitivity to collagen and its derivatives

    • Patients with sensitivity to porcine-derived products

    • Patients with sensitivity to honey

    • Third degree burns

    • Infections or contamination in the wound site

    • Control of bleeding

    • Children and infant patients under 10kg / 22lbs

    Usage Information

    • Users should follow the most recent procedures and best practices for wound management to complete wound preparation, application of APIS® and application of secondary dressings.

    • Remove APIS® and discontinue use if signs of sensitivity appear.

    • Do not use APIS® after the expiration date stated on the product label.

    Contact a health care professional if:

    • Signs of infection occur (e.g. increased pain)

    • There is a change in wound color and/or odor

    • The wound does not begin to show signs of healing, or

    • Any other unexpected symptom

We're here to support your patients!

  • Got questions?

    The safety and well-being of our patients and those that care for them is what matters most. You can count on us through every step.

    Contact

  • Request More Information

    Learn more about the APIS® difference.

    Inquire

  • Clinical In-Service

    Request a clinical in-service visit with Dr. Isaac Rodriguez, the co-inventor of APIS® and Chief Science Officer at SweetBio®.

    Schedule